{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:57:47Z","timestamp":1792277867945,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a chronic, disabling brain disorder. Melatonin, a circadian regulator with anti-inflammatory and antinociceptive actions, has been proposed for migraine prevention. We evaluated the efficacy and safety of melatonin for prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Cochrane, Scopus, Embase, and Web of Science (September 29, 2024) for randomised controlled trials (RCTs) comparing melatonin with placebo or other active drugs. Outcomes were analysed as change from baseline to last follow-up using mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine RCTs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009788) were included. Versus placebo, melatonin reduced attack duration (MD -4.98\u00a0h; 95% CI -9.30 to -0.67;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), headache days (MD -1.54 days; 95% CI -2.50 to -0.58;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), headache severity (MD -2.08; 95% CI -2.91 to -1.26;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and analgesic use (MD -1.38; 95% CI -2.41 to -0.36;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Melatonin also increased the response rate (\u2265\u200950% reduction in monthly headache frequency) (RR 1.38; 95% CI 1.11\u20131.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and improved sleep quality (PSQI: MD -1.64; 95% CI -2.85 to -0.42;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008) and disability (MIDAS: SMD \u2212\u20094.07; 95% CI -5.45 to -2.69;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Compared with amitriptyline, melatonin was generally less effective for attack duration and severity, with no consistent advantage on analgesic use or response; however, melatonin showed a more favourable tolerability profile, including lower risk of sleepiness (RR 0.49; 95% CI 0.28\u20130.87;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Melatonin demonstrates benefits over placebo for reducing migraine burden and improving patient-reported outcomes, with a favourable safety profile. While amitriptyline remains more potent for several efficacy endpoints, melatonin represents a reasonable preventive option, particularly as an adjunct during titration of first-line agents. Further head-to-head trials with standardised dosing and longer follow-up are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11916-025-01461-5","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:42:19Z","timestamp":1770014539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-2429","authenticated-orcid":false,"given":"Moaz Elsayed","family":"Abouelmagd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Aldemerdash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8299-6945","authenticated-orcid":false,"given":"Abdallah Ahmad","family":"Khatatbeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2871-9925","authenticated-orcid":false,"given":"Ahmed S.A","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2749-8982","authenticated-orcid":false,"given":"Salma","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0001-9830","authenticated-orcid":false,"given":"Esraa M.","family":"AlEdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aldemerdash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-252X","authenticated-orcid":false,"given":"Teshamae S.","family":"Monteith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"1461_CR1","doi-asserted-by":"publisher","unstructured":"Simmonds L, Mehta D, Cheema S, Matharu M. Chapter 3 - Epidemiology of migraine. In: Swanson JW, Matharu M, eds. Handbook of Clinical Neurology. Vol 198. Migraine Biology, Diagnosis, and Co-Morbidities. Elsevier; 2023:31\u201338. https:\/\/doi.org\/10.1016\/B978-0-12-823356-6.00017-2","DOI":"10.1016\/B978-0-12-823356-6.00017-2"},{"issue":"22","key":"1461_CR2","doi-asserted-by":"publisher","first-page":"e2224","DOI":"10.1212\/WNL.0000000000207240","volume":"100","author":"B Benkli","year":"2023","unstructured":"Benkli B, Kim SY, Koike N, et al. Circadian features of cluster headache and migraine: a systematic review, meta-analysis, and genetic analysis. Neurology. 2023;100(22):e2224\u201336. https:\/\/doi.org\/10.1212\/WNL.0000000000207240.","journal-title":"Neurology"},{"issue":"4","key":"1461_CR3","first-page":"383","volume":"6","author":"JJ Gagnier","year":"2001","unstructured":"Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. Altern Med Rev J Clin Ther. 2001;6(4):383\u20139.","journal-title":"Altern Med Rev J Clin Ther"},{"issue":"3","key":"1461_CR4","doi-asserted-by":"publisher","first-page":"e14099","DOI":"10.1097\/MD.0000000000014099","volume":"98","author":"R Long","year":"2019","unstructured":"Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Med (Baltim). 2019;98(3):e14099. https:\/\/doi.org\/10.1097\/MD.0000000000014099.","journal-title":"Med (Baltim)"},{"issue":"3\u20134","key":"1461_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.11607\/ofph.3211","volume":"36","author":"HM Puliappadamb","year":"2022","unstructured":"Puliappadamb HM, Maiti R, Mishra A, Jena M, Mishra BR. Efficacy and safety of melatonin as prophylaxis for migraine in adults: A Meta-analysis. J Oral Facial Pain Headache. 2022;36(3\u20134):207\u201319. https:\/\/doi.org\/10.11607\/ofph.3211.","journal-title":"J Oral Facial Pain Headache"},{"key":"1461_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3389\/fneur.2019.00606","volume":"10","author":"Z Chen","year":"2019","unstructured":"Chen Z, Chen X, Liu M, Ma L, Yu S. Volume of hypothalamus as a diagnostic biomarker of chronic migraine. Front Neurol. 2019;10:606. https:\/\/doi.org\/10.3389\/fneur.2019.00606.","journal-title":"Front Neurol"},{"issue":"Pt 1","key":"1461_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/brain\/awt320","volume":"137","author":"FH Maniyar","year":"2014","unstructured":"Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain J Neurol. 2014;137(Pt 1):232\u201341. https:\/\/doi.org\/10.1093\/brain\/awt320.","journal-title":"Brain J Neurol"},{"issue":"5","key":"1461_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s11916-011-0219-x","volume":"15","author":"MFP Peres","year":"2011","unstructured":"Peres MFP. Melatonin for migraine prevention. Curr Pain Headache Rep. 2011;15(5):334\u20135. https:\/\/doi.org\/10.1007\/s11916-011-0219-x.","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"1461_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1517\/13543784.15.4.367","volume":"15","author":"MF Peres","year":"2006","unstructured":"Peres MF, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006;15(4):367\u201375. https:\/\/doi.org\/10.1517\/13543784.15.4.367.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1461_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00023210-200620050-00001","volume":"20","author":"B Vogler","year":"2006","unstructured":"Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME. Role of melatonin in the pathophysiology of migraine: implications for treatment. CNS Drugs. 2006;20(5):343\u201350. https:\/\/doi.org\/10.2165\/00023210-200620050-00001.","journal-title":"CNS Drugs"},{"key":"1461_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1461_CR12","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Accessed November 28. 2024. https:\/\/training.cochrane.org\/handbook"},{"issue":"1","key":"1461_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1461_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ Published Online August. 2019;28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ Published Online August"},{"key":"1461_CR15","unstructured":"R: The R Project for Statistical Computing. Accessed November 28, 2024. https:\/\/www.r-project.org\/"},{"issue":"4","key":"1461_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"issue":"7109","key":"1461_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"1","key":"1461_CR18","first-page":"47","volume":"12","author":"R Fallah","year":"2018","unstructured":"Fallah R, Fazelishoroki F, Sekhavat L. A randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children. Iran J Child Neurol. 2018;12(1):47\u201354.","journal-title":"Iran J Child Neurol"},{"key":"1461_CR19","unstructured":"Comparison of Efficacy and Tolerability of Melatonin and Amitriptyline in Children Suffering with Migraine. Accessed November 28. 2024. https:\/\/medforum.pk\/article\/comparison-of-efficacy-and-tolerability-of-melatonin-and-amitriptyline-in-children-suffering-with-migraine"},{"issue":"10","key":"1461_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","volume":"87","author":"AL Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MFP. Randomised clinical trial comparing melatonin 3\u00a0mg, amitriptyline 25\u00a0mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016;87(10):1127\u201332. https:\/\/doi.org\/10.1136\/jnnp-2016-313458.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"1461_CR21","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1212\/WNL.0b013e3181f9618c","volume":"75","author":"KB Alstadhaug","year":"2010","unstructured":"Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010;75(17):1527\u201332. https:\/\/doi.org\/10.1212\/WNL.0b013e3181f9618c.","journal-title":"Neurology"},{"issue":"1","key":"1461_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12883-023-03516-9","volume":"24","author":"K Farzin","year":"2024","unstructured":"Farzin K, Kheiltash A, Tafakhori A, Nakhjiri NE, Sabet MS, Nayeri ND. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024;24(1):2. https:\/\/doi.org\/10.1186\/s12883-023-03516-9.","journal-title":"BMC Neurol"},{"issue":"3","key":"1461_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.22037\/ijcn.v18i3.42197","volume":"18","author":"A Fayyazi","year":"2024","unstructured":"Fayyazi A, Abbasian P, Hosseini SMS, Mohammadi Y, Bazmamoum H. Efficacy of melatonin administration in reducing headaches in children with migraines without sleep disorders. Iran J Child Neurol. 2024;18(3):57\u201363. https:\/\/doi.org\/10.22037\/ijcn.v18i3.42197.","journal-title":"Iran J Child Neurol"},{"issue":"9","key":"1461_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/head.14600","volume":"63","author":"AA Gelfand","year":"2023","unstructured":"Gelfand AA, Allen IE, Grimes B, et al. Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo\u2010controlled trial after single\u2010blind placebo lead\u2010in. Headache J Head Face Pain. 2023;63(9):1314\u201326. https:\/\/doi.org\/10.1111\/head.14600.","journal-title":"Headache J Head Face Pain"},{"issue":"5","key":"1461_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.30476\/ijms.2023.97782.2965","volume":"49","author":"A Mehramiri","year":"2024","unstructured":"Mehramiri A, Shalilahmadi D, Mohamadianinejad SE, Kouti L, Hosseinpour Y. The effect of melatonin on reducing the frequency and severity of migraine attacks: A Double-Blind, randomized clinical trial. Iran J Med Sci. 2024;49(5):313\u201321. https:\/\/doi.org\/10.30476\/ijms.2023.97782.2965.","journal-title":"Iran J Med Sci"},{"issue":"4","key":"1461_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/RNN-160704","volume":"35","author":"M Ebrahimi-Monfared","year":"2017","unstructured":"Ebrahimi-Monfared M, Sharafkhah M, Abdolrazaghnejad A, Mohammadbeigi A, Faraji F. Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. Restor Neurol Neurosci. 2017;35(4):385\u201393. https:\/\/doi.org\/10.3233\/RNN-160704.","journal-title":"Restor Neurol Neurosci"},{"issue":"6","key":"1461_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.clinthera.2008.06.005","volume":"30","author":"FR Taylor","year":"2008","unstructured":"Taylor FR. Weight change associated with the use of migraine-preventive medications. Clin Ther. 2008;30(6):1069\u201380. https:\/\/doi.org\/10.1016\/j.clinthera.2008.06.005.","journal-title":"Clin Ther"},{"key":"1461_CR28","unstructured":"Thour A, Marwaha R. Amitriptyline. In: StatPearls. StatPearls Publishing; 2024. Accessed November 28, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537225\/"},{"issue":"6","key":"1461_CR29","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s10571-023-01324-w","volume":"43","author":"SB Ahmad","year":"2023","unstructured":"Ahmad SB, Ali A, Bilal M, et al. Melatonin and health: insights of melatonin Action, biological Functions, and associated disorders. Cell Mol Neurobiol. 2023;43(6):2437\u201358. https:\/\/doi.org\/10.1007\/s10571-023-01324-w.","journal-title":"Cell Mol Neurobiol"},{"issue":"15","key":"1461_CR30","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","volume":"171","author":"B Guardiola-Lemaitre","year":"2014","unstructured":"Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Moca\u00ebr E. Agomelatine: mechanism of action and Pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171(15):3604\u201319. https:\/\/doi.org\/10.1111\/bph.12720.","journal-title":"Br J Pharmacol"},{"key":"1461_CR31","doi-asserted-by":"publisher","unstructured":"Nnadi E, Masara M, Offor R, et al. (2025) Abstract 4371606: Effect of Long-term Melatonin Supplementation on Incidence of Heart Failure in Patients with Insomnia. Circulation. 152(Suppl_3). https:\/\/doi.org\/10.1161\/circ.152.suppl_3.4371606","DOI":"10.1161\/circ.152.suppl_3.4371606"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-025-01461-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:42:23Z","timestamp":1770014543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-025-01461-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1007\/s11916-025-01461-5","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Teshamae Monteith has the following disclosures over the past three years: clinical trial site principal investigator for studies sponsored by AbbVie, Eli Lilly, Ipsen, Merz and Rehaler, participation in advisory board\/consultancy for AbbVie, Teva, e-Neura, Lundbeck, Novartis, Axsome, Therapeutics, Merz, Amneal, and Pfizer, an educational grant from Amgen and AbbVie, personal fees from Medscape, Massachusetts Medical Society, American Headache Society, American Academy of Neurology, Canadian Headache Society, Academic CME, AbbVie, Novartis, unpaid co-author for research funded by AbbVie, Pfizer\/Biohaven, and Theranica. She has done editorial work for\n                      Cephalalgia\n                      and Continuum Audio and is on the editorial board for\n                      Neurology\n                      , American Migraine Foundation,\n                      New England Journal of Medicine\n                      Clnician, and\n                      Brain and Life Magazine\n                      . She has provided unpaid service on the board of directors for the International Headache Society (2021-2023) and currently sits on the executive board for the Florida Society of Neurology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"25"}}